Women's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

831 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-07

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to describe and assess participants' satisfaction with current vulvovaginal atrophy (VVA) treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Performance and Safety of the VITA AV Clinical System

NCT06207227

Vaginal Atrophy

COMPLETED NA

Laser Therapy for Vulvovaginal Symptoms in Breast Cancer Patients

NCT03628092

Vulvovaginal Atrophy Genitourinary Symptoms and Ill-Defined Conditions

UNKNOWN NA

Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy

NCT01404728

Malignancies Stenosis of Vagina

COMPLETED

Fractional Handpiece With CO2 Laser: Fractional Ablative Laser Treatment of Vulvovaginal Atrophy

NCT03271944

Vulvovaginal Atrophy

UNKNOWN NA

Treatment of Vaginal Atrophy With Low Intensity Nanosecond Neodymium Laser

NCT05335317

Postmenopausal Period Vaginal Atrophy Vaginal Prolapse

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is designed as a multicenter, cross-sectional, descriptive, observational study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vulvovaginal Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Postmenopausal Women

Participants who sign an informed consent will be asked to complete study questionnaires at a single visit that coincides with a normal healthcare visit. No other study procedures will be performed.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women with natural menopause established for at least one year.
* Absence of menstruation for at least one year.
* Mild, moderate or severe VVA diagnosis.
* Currently under treatment with either Ospemifene, Local Oestrogen Therapy or moisturizers for at least 3 months in accordance with the approved SmPC and/or Patient Leaflet
* Patients providing writing informed consent for participating in the study.

Exclusion Criteria

* Women who have never been previously treated for VVA
* Women who have discontinued their VVA treatment due to a contraindication in the study group drug.
* Patients using more than one VVA treatment at a time (except for lubricants).
* Breastfeeding, pregnancy or under any kind of systemic hormonal treatment that causes amenorrhea.
* Local phytotherapy for VVA.

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No